Transcriptional Targeting of Primary and Metastatic Tumor Neovasculature by an Adenoviral Type 5 Roundabout4 Vector in Mice
Open Access
- 23 December 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83933
Abstract
New approaches targeting metastatic neovasculature are needed. Payload capacity, cellular transduction efficiency, and first-pass cellular uptake following systemic vector administration, motivates persistent interest in tumor vascular endothelial cell (EC) adenoviral (Ad) vector targeting. While EC transductional and transcriptional targeting has been accomplished, vector administration approaches of limited clinical utility, lack of tumor-wide EC expression quantification, and failure to address avid liver sequestration, challenged prior work. Here, we intravenously injected an Ad vector containing 3 kb of the human roundabout4 (ROBO4) enhancer/promoter transcriptionally regulating an enhanced green fluorescent protein (EGFP) reporter into immunodeficient mice bearing 786-O renal cell carcinoma subcutaneous (SC) xenografts and kidney orthotopic (KO) tumors. Initial experiments performed in human coxsackie virus and adenovirus receptor (hCAR) transgenic:Rag2 knockout mice revealed multiple ECs with high-level Ad5ROBO4-EGFP expression throughout KO and SC tumors. In contrast, Ad5CMV-EGFP was sporadically expressed in a few tumor vascular ECs and stromal cells. As the hCAR transgene also facilitated Ad5ROBO4 and control Ad5CMV vector EC expression in multiple host organs, follow-on experiments engaged warfarin-mediated liver vector detargeting in hCAR non-transgenic mice. Ad5ROBO4-mediated EC expression was undetectable in most host organs, while the frequencies of vector expressing intratumoral vessels and whole tumor EGFP protein levels remained elevated. In contrast, AdCMV vector expression was only detectable in one or two stromal cells throughout the whole tumor. The Ad5ROBO4 vector, in conjunction with liver detargeting, provides tractable genetic access for in-vivo EC genetic engineering in malignancies.Keywords
This publication has 67 references indexed in Scilit:
- Endothelial and perivascular cells maintain haematopoietic stem cellsNature, 2012
- Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectinsJournal of Controlled Release, 2011
- Robo4 Cooperates with Cxcr4 to Specify Hematopoietic Stem Cell Localization to Bone Marrow NichesCell Stem Cell, 2011
- Adenovirus2010
- Slit2–Robo4 signalling promotes vascular stability by blocking Arf6 activityNature Cell Biology, 2009
- Transcriptional targeting of tumor endothelial cells for gene therapyAdvanced Drug Delivery Reviews, 2009
- Combinatorial Regulation of Endothelial Gene Expression by Ets and Forkhead Transcription FactorsCell, 2008
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008
- Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cellsCancer Gene Therapy, 2008
- Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational controlBreast Cancer Research and Treatment, 2007